Olema Pharmaceuticals grants stock options to four employees, totaling 205,000 shares, under the 2022 Inducement Plan.
Quiver AI Summary
Olema Pharmaceuticals, Inc. has announced the grant of stock options to four new employees, allowing them to purchase a total of 205,000 shares of common stock. This decision, made by the Compensation Committee of Olema's Board of Directors, is in accordance with the Company’s 2022 Inducement Plan and Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, with a portion vesting after one year and the remaining in monthly installments, contingent on continued employment. The options have an exercise price of $24.02, matching the latest stock price on March 2, 2026, and have a ten-year term. Olema is focused on developing targeted therapies for breast cancer, highlighting its lead candidate, palazestrant, currently in Phase 3 trials.
Potential Positives
- The company has expanded its team by granting stock options to four new employees, indicating growth and investment in talent.
- The stock options have a significant value associated with the exercise price being aligned with the last reported sale price of the Company's common stock, demonstrating confidence in the company's future performance.
- The granting of stock options is part of Olema's 2022 Inducement Plan, which reinforces the company's commitment to competitive employee incentives and retention.
- Olema is advancing a strong pipeline of novel therapies, including its lead product candidate, palazestrant (OP-1250), which is currently in two Phase 3 clinical trials, highlighting the company's ongoing commitment to innovation in breast cancer treatment.
Potential Negatives
- Granting of stock options to new employees may indicate high turnover or a need to attract talent, suggesting potential challenges in recruitment or employee retention.
- The exercise price of $24.02 per share reflects the last reported sale price, which may indicate the company's stock performance is under pressure, affecting overall investor sentiment.
- Being a clinical-stage biopharmaceutical company, Olema is heavily reliant on the success of its drug candidates, and any failure in their clinical trials could lead to significant financial and reputational consequences.
FAQ
What stock options were granted by Olema Pharmaceuticals?
Olema granted stock options for 205,000 shares to four new employees, effective March 2, 2026.
How do the stock options for new employees vest?
The stock options vest over four years, with 25% vesting on the first anniversary and the rest in monthly installments.
What is the exercise price for the stock options?
The exercise price for the stock options is $24.02 per share, equal to the last reported sale price on March 2, 2026.
Which plan are the stock options granted under?
The stock options are granted under Olema's 2022 Inducement Plan, approved by the Compensation Committee.
What is Olema Oncology's focus as a biopharmaceutical company?
Olema Oncology focuses on developing targeted therapies for breast cancer and improving patient outcomes in endocrine-driven cancers.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OLMA Insider Trading Activity
$OLMA insiders have traded $OLMA stock on the open market 24 times in the past 6 months. Of those trades, 0 have been purchases and 24 have been sales.
Here’s a breakdown of recent trading of $OLMA stock by insiders over the last 6 months:
- IAN T CLARK has made 0 purchases and 3 sales selling 264,800 shares for an estimated $7,873,109.
- NASEEM ZOJWALLA (Chief Medical Officer) has made 0 purchases and 4 sales selling 269,509 shares for an estimated $7,530,147.
- DAVID C. MYLES (CH. DISCOV. & NON-CLIN DEV OFF) has made 0 purchases and 8 sales selling 161,000 shares for an estimated $4,660,772.
- SHANE WILLIAM CHARLES KOVACS (CH. OPERATING & FINANCIAL OFF.) has made 0 purchases and 2 sales selling 103,822 shares for an estimated $2,980,054.
- CYRUS HARMON has made 0 purchases and 7 sales selling 41,370 shares for an estimated $657,435.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$OLMA Hedge Fund Activity
We have seen 133 institutional investors add shares of $OLMA stock to their portfolio, and 61 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 4,993,670 shares (+16972.6%) to their portfolio in Q4 2025, for an estimated $124,841,750
- DEEP TRACK CAPITAL, LP removed 3,470,172 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $86,754,300
- SIREN, L.L.C. added 3,300,700 shares (+inf%) to their portfolio in Q4 2025, for an estimated $82,517,500
- JANUS HENDERSON GROUP PLC added 3,124,345 shares (+87.1%) to their portfolio in Q4 2025, for an estimated $78,108,625
- CORMORANT ASSET MANAGEMENT, LP added 2,750,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $68,750,000
- RA CAPITAL MANAGEMENT, L.P. added 2,600,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $65,000,000
- MPM BIOIMPACT LLC removed 2,378,762 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $23,288,079
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$OLMA Analyst Ratings
Wall Street analysts have issued reports on $OLMA in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 01/07/2026
- Piper Sandler issued a "Overweight" rating on 01/07/2026
- Citigroup issued a "Buy" rating on 12/12/2025
- Goldman Sachs issued a "Buy" rating on 11/21/2025
- JP Morgan issued a "Overweight" rating on 11/18/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/18/2025
- Oppenheimer issued a "Outperform" rating on 11/18/2025
To track analyst ratings and price targets for $OLMA, check out Quiver Quantitative's $OLMA forecast page.
$OLMA Price Targets
Multiple analysts have issued price targets for $OLMA recently. We have seen 8 analysts offer price targets for $OLMA in the last 6 months, with a median target of $45.0.
Here are some recent targets:
- Laura Prendergast from Stifel set a target price of $48.0 on 02/11/2026
- Michael Yee from UBS set a target price of $45.0 on 01/07/2026
- Yigal Nochomovitz from Citigroup set a target price of $60.0 on 12/12/2025
- Matthew Biegler from Oppenheimer set a target price of $48.0 on 12/11/2025
- Richard Law from Goldman Sachs set a target price of $38.0 on 12/11/2025
- Emily Bodnar from HC Wainwright & Co. set a target price of $45.0 on 12/11/2025
- Anupam Rama from JP Morgan set a target price of $32.0 on 11/18/2025
Full Release
SAN FRANCISCO, March 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 205,000 shares of the Company's common stock, effective as of March 2, 2026. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of $24.02 per share, equal to the last reported sale price of the Company's common stock as reported by Nasdaq on March 2, 2026. The stock options are subject to the terms of the Olema Pharmaceuticals, Inc., 2022 Inducement Plan.
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit
www.olema.com
.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
[email protected]
